Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ana4.6
Anastrozole – Forschung
Überwiegend Mechanismus / Beobachtung
34 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Anastrozole sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 212 Teilnehmenden.
Basierend auf 34 Studien · 6 Meta-Analysen · 19 RCTs · 41,913 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Breast cancer (approved)
Überwiegend Mechanismus / Beobachtung23 Studien
Testosterone & male hormonesErhöht zuverlässig das endogene Testosteron und senkt moderat das Estradiol bei älteren und adipösen hypogonadalen Männern · Wochen täglicher Einnahme
Überwiegend Mechanismus / Beobachtung16 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung8 Studien
Bone health (trade-off)
Überwiegend Mechanismus / Beobachtung3 Studien
Fertility & reproductive
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
27 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
200520152026
1Meta-Analysen=8,482 · very large study2025
Although newer combination therapies are being adopted, the agents explored in this review are still widely used in clinical practice for HR+ BC.
Okwor VC, Okwor JC, Ukwuoma MK, Mitha SB, Nweke MC. · Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2025)
ORR and PFS between aromatase inhibitors (AIs) and other hormonal therapies: selective oestrogen receptor degrader, selective oestrogen modulator (SERM) and androgen inhibitors showed no significant difference (OR = 1.122 [0.917-1.374], p = 0.263; OR = 0.010 [0.000-1.292], p = 0.063), respectively.
Subgroup analysis showed a statistically significant difference in ORR in favour of patients who received SERM compared to AI (OR = 1.362 [1.033-1.795], p = 0.028).
For OS, no significant difference was observed among anastrozole, letrozole, and exemestane recepients (OR = 1.718 [0.021-139.128], p = 0.809).
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA. · JAMA oncology (2025)
Importance Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) has demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/ERBB2 (formerly HER2)-negative early breast cancer.
Results Among 5101 patients included in the analysis (median [range] age, 52 [24-90] years; 5081 [99.6%] female), the median follow-up for iDFS was 44.2 months (range, 0-63 months).
Ribociclib plus NSAI continued to show iDFS benefit over NSAI alone (hazard ratio, 0.72; 95% CI, 0.61-0.84), with 3-year iDFS rates of 90.8% vs 88.1% (difference, 2.7 percentage points) and 4-year rates of 88.5% vs 83.6% (difference, 4.9 percentage points).
However, BMI should be considered in anastrozole therapy due to differential effects on DFS and adverse events.
Lin X, Sun H, Wei X, Xie M, Chen L, Hu CT, Cai J. · Clinical nutrition ESPEN (2025)
Normal-weight patients on tamoxifen had a greater risk of bone pain (RR = 1.25, P = 0.03).
Further MR analysis revealed no causal link between BMI and 5-year or 15-year survival rates in endocrine-treated patients (5-year HR = 0.7923, 95 % Confidence Interval (CI)[0.2053, 3.0581], P = 0.7355; 15-year HR = 0.9793, 95 % CI [0.7121, 1.3469], P = 0.898).
Conclusion Current meta-analysis and MR findings suggest no significant link between BMI and the overall efficacy of endocrine therapy in breast cancer.
The risk-benefit ratio should be determined for every patient to avoid overtreatment of a significant proportion of patients.
Taha AM, Kamel HA, Khlidj Y, Salem DS, Saed SAA, Abouelmagd K, Nguyen D, Shash E, Chapagain S, Kassem L. · Medicine (2025)
All patients had a node-negative disease, with 84.4% older than 60 years and only 10.4% had tumors larger than 2 cm.
The median follow-up was 9.7 years (95% CI: 5.1-11.3).
The survival risk for any local recurrence for patients with no radiotherapy was significantly higher than for those who used PORT (HR: 6.3; 95% CI: 4.17-9.52).
These findings contribute to a comprehensive understanding of prognostic factors, targeted therapies, and survival outcomes in endometrial cancer, emphasizing the need for further research and clinical trials for optimal disease management.
Raza A, Abaidullah R, Alshabrmi FM, Fatima I. · Irish journal of medical science (2025)
The meta-analysis indicates that targeted therapies do not significantly improve PFS but reduce adverse effects.
Chemotherapy does not considerably improve survival rates, and interventions show no significant difference in prognostic factors.
Conclusion In conclusion, anastrozole and vistusertib emerge as effective targeted therapies for endometrial cancer, supported by clinical trial evidence demonstrating reduced PFS and improved protein detection.
Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Rimawi MF, Weiss A, Winer EP, Hunt KK, Perou CM, Ellis MJ, Partridge AH, Carey LA. · JAMA oncology (2024)
Objective To determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual disease (referred to as endocrine-sensitive disease) over anastrozole alone.
Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or >66%)/ERBB2-negative breast cancer were included.
Tumor Ki67 was assessed at week 4 and optionally at week 12, and if greater than 10% at either time point, the patient switched to neoadjuvant chemotherapy or immediate surgery.
These findings underscore dysregulated oncogenic pathways as potential resistance mechanisms and biomarkers of response to CDK4/6i.
Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX. · Nature communications (2026)
Thirty-four patients with clinical stage II/III ER + /HER2- BCs resistant to standard neoadjuvant endocrine therapy (on-treatment Ki67 > 10%) received neoadjuvant ANA/PAL, with serial biopsies analyzed.
The primary endpoint, complete cell cycle arrest (CCCA; Ki67 C1D15 ≤ 2.7% at cycle 1, day 15), was achieved in 57.6% of patients (95%CI: 39.2-74.5%).
Resistance to ANA/PAL (Ki67 C1D15 > 10%) was associated with higher pre-treatment tumor grade, Ki67, and specific PAM50 subtypes.
Funding Genentech, Howard Hughes Medical Institute, National Foundation for Cancer Research, and Breast Cancer Research Foundation.
Wander SA, Lloyd MR, Keenan JC, Scott EC, Niemierko A, Spring LM, Fell GG, Shin J, Isakoff SJ, Moy B, Ryan L, Padden S, Fisher E, Newton A, Habin KR, Viscosi-Spieler ET, Scarpetti L, Varkaris A, Ellisen LW, Dubash T, Che D, Patel PS, de la Cruz FF, Sutaria DS, Sane RS, Micalizzi DS, Maheswaran S, Haber DA, Juric D, Bardia A. · The Lancet. Oncology (2026)
All patients were female (77 [100%]); 75 were White (97%) and two (3%) were Asian.
The median age was 62 years (range 32-88) and 66 (86%) of 77 patients received previous CDK4/6 inhibitor (median number of previous lines was 3 [range 1-13]).
Median progression-free survival was 5·5 months (95% CI 3·8-7·4).
Eraso Y, Stewart D, Edwards R, Nanray B, Cochrane J. · JMIR cancer (2026)
Background Approximately 80% of breast cancers are estrogen receptor positive, and following initial tumor treatment, patients are prescribed hormone therapy (HT) drugs (tamoxifen, letrozole, anastrozole, and exemestane) for 5-10 years.
It includes recording side effects from brands alongside physical, psychological, and environmental factors; actions taken to manage symptoms; and problem-solving and planning before a medication consultation to facilitate personalized feedback from pharmacists.
Conclusions We preliminarily developed an intervention that appears engaging, relevant, and acceptable for patients to self-monitor their symptoms.
Extended anastrozole therapy halved the risk of DR and BCSM in patients with luminal A-like tumours, whereas no effect was seen in patients with luminal B-like tumours.
Lammers SWM, Geurts SME, Hermans KEPE, Kooreman LFS, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, Honkoop AH, van den Berkmortel FWPJ, de Roos WK, Linn SC, Imholz ALT, Vriens IJH, Tjan-Heijnen VCG, Dutch Breast Cancer Research Group (BOOG) for the DATA investigators. · ESMO open (2025)
Patients with luminal B-like tumours experienced a higher risk of DR [subdistribution hazard ratio (sHR) 1.44, 95% confidence interval (CI) 1.03-2.01, P = 0.03] and BCSM (sHR 1.68, 95% CI 1.15-2.45, P = 0.008) than patients with luminal A-like tumours.
Conclusion In patients with hormone receptor-positive breast cancer, the luminal B-like subtype was associated with a significantly worse prognosis when compared with the luminal A-like subtype.
Extended anastrozole therapy halved the risk of DR and BCSM in patients with luminal A-like tumours, whereas no effect was seen in patients with luminal B-like tumours.
Lastly, we speculate on the potential role of routine measurement of oestradiol in managing risk and achieving prevention of breast cancer.
Cuzick J, Dowsett M. · British journal of cancer (2025)
We then focus on results from the comparative trials of aromatase inhibitors (AIs) versus tamoxifen and the extension of the use of AIs in trials for prevention.
We describe the relationship between plasma levels of oestradiol and its major protein binder, sex hormone binding globulin, on the development of oestrogen receptor positive breast cancer and how these impact on the preventive effect of the AI, anastrozole, in postmenopausal women.
Lastly, we speculate on the potential role of routine measurement of oestradiol in managing risk and achieving prevention of breast cancer.
Further large-scale, high-quality studies are needed to confirm these findings and refine preventive treatment recommendations.
Spagnolo L, Tienforti D, Moretto C, Tonni C, Donatelli V, Ferranti A, Puocci G, Capuano C, Barbonetti A. · Journal of endocrinological investigation (2025)
Risk ratios (RR) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models, and heterogeneity was evaluated with the I² statistic.
Tamoxifen significantly reduced the risk of breast events by 82% (RR: 0.18, 95% CI: 0.08-0.38 for gynecomastia and RR: 0.18, 95% CI: 0.07-0.43 for breast pain).
Radiotherapy reduced gynecomastia risk by 52% (RR: 0.48, 95% CI: 0.38-0.59) and breast pain by 34% (RR: 0.66, 95% CI: 0.48-0.90).
Data from FALCON are consistent with published evidence of long-term clinical benefit with fulvestrant and other endocrine therapies in the subset of patients with nonvisceral disease.
Robertson JFR, Shao Z, Noguchi S, Bondarenko I, Panasci L, Singh S, Subramaniam S, Ellis MJ. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025)
The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
The final OS analysis was triggered at ≥65% maturity and ≥8 years since the last patient was enrolled.
At the data cutoff (July 11, 2022), 314 (68.0%) of 462 patients had died (fulvestrant, 157/230 [68.3%], anastrozole, 157/232 [67.7%]).
Finally, when lymphoid aggregates are encountered in specimens from patients with breast cancer, a clinical history of hormonal therapy should alert the pathologist for a possibility of lymphoma.
Kitagawa Y, Nassiri M, Mesa H, Prakash J, Popnikolov N. · Journal of medical case reports (2025)
However, further studies are necessary to clarify the roles of steroid hormones in pathogenesis of apocrine carcinoma and follicular lymphoma.
This case also illustrates the importance of patient follow-up during and after aromatase inhibitor therapy.
Appropriate surveillance for lymphoma may also be considered for those patients.
Funding Cancer Research UK, National Health and Medical Research Council (Australia), Breast Cancer Research Foundation, and DaCosta Fund.
Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, Bonanni B, Loibl S, Holli K, Evans DG, Cummings S, Dowsett M. · The Lancet. Oncology (2024)
Profile likelihood 95% CIs were used to indicate the precision of estimates.
Median follow-up time was 131 months (IQR 106-156), during which 85 (4·4%) cases of breast cancer in the anastrozole group and 165 (8·5%) in the placebo group were identified.
A trend of increasing breast cancer risk with increasing oestradiol-SHBG ratio was found in the placebo group (trend per quartile 1·25 [95% CI 1·08 to 1·45], p=0·0033), but not in the anastrozole group (1·06 [0·86 to 1·30], p=0·60).
Anastrozole significantly improved disease-free survival, time to recurrence, and time to distant recurrence versus tamoxifen, but fractures were more frequent during active anastrozole treatment.
T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant demonstrated preliminary clinical activity in patients with HER2-low mBC.
Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F. · Clinical cancer research : an official journal of the American Association for Cancer Research (2026)
For T-DXd + capecitabine, grade ≥3 adverse events (AE) occurred in 55% (11/20) of patients, and the ORR was 60%.
For T-DXd + capivasertib, grade ≥3 AEs occurred in 67.5% (27/40) of patients, and the ORR was 60%.
For T-DXd + anastrozole, grade ≥3 AEs occurred in 47.6% (10/21) of patients, and the ORR was 71.4%.